ArticleEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)2020
HASPIN kinase inhibitor CHR-6494 suppresses intestinal polyp development, cachexia, and hypogonadism in Apcmin/+ mice.
Article in European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Advances in chemoprevention of familial adenomatous polyposis.Frontiers in oncology · 2026Review
- Oral Ingestion of Bean Sprouts Containing the HASPIN Inhibitor Coumestrol Increased Blood Testosterone Levels in Men.Biology · 2025Article
- Article
- A Haspin promoter element induces tissue-specific methylation of a transcription region and the regulation of gene expression in mouse ova.Cell journal · 2022Article
- Analysis of Ser/Thr Kinase HASPIN-Interacting Proteins in the Spermatids.International journal of molecular sciences · 2022Article
- Inhibitory Effect of the HASPIN Inhibitor CHR-6494 on BxPC-3-Luc, A Luciferase-Expressing Pancreatic Cancer Cell Line.Cell journal · 2022Article
- Pervasiveness of intronless genes expressed in haploid germ cell differentiation.Reproductive medicine and biology · 2021Review
- Evaluation of the antiproliferative effects of the HASPIN inhibitor CHR-6494 in breast cancer cell lines.PloS one · 2021Article
- Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.Biochimica et biophysica acta. Reviews on cancer · 2020Review
- Bioinformatic Analysis Reveals GSG2 as a Potential Target for Breast Cancer Therapy.Open life sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HASPIN has been identified as a nuclear Ser/Thr kinase specifically expressed in haploid germ cells. HASPIN kinase inhibitors were recently isolated, and their antitumor activity reported. Colorectal cancer occurs with high incidence worldwide. In this study, we examined whether HASPIN inhibitor CHR-6494 suppresses cancer progression in Apc mice, a familial colon tumor disease model. Mice were treated by intraperitoneal injection of CHR-6494 for 50 days. Following the treatment period, intestinal polyps were counted and testosterone and spermatogenesis levels were observed. Intraperitoneal administration of CHR-6494 significantly inhibited intestinal polyp development and recovered body weight in Apc mice. Although spermatogenesis was inhibited with increasing age in Apc mice, CHR-6494 significantly improved blood testosterone levels and spermatogenesis. Our results suggest that HASPIN inhibitors may be useful as anti-cancer agents and for the treatment of hypogonadism in colorectal cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.